Pharmacodynamic dihydropyridine derivative – blocker “slow” calcium channels II generation, has antianginal and hypotensive action. Communicating with the dihydropyridine receptor, blocks calcium channels reduces the transmembrane passage of calcium ions into the cell (mainly in vascular smooth muscle cells than cardiac myocytes). Antianginal effect is due to the expansion of the coronary and peripheral arteries and arterioles: angina reduces the severity of myocardial ischemia; expanding peripheral arterioles, decreases total peripheral vascular resistance, decreases the preload on the heart, reducing myocardial oxygen demand. Expanding the major coronary arteries and arterioles in the unaltered and ischemic myocardial areas, increases the supply of oxygen to the myocardium (especially in vasospastic angina); It prevents the development of constriction of the coronary arteries (including those caused by smoking). In patients with angina single daily dose increases the run-time physical activity slows the development of angina and ‘ischemic »ST-segment depression, reduces the frequency of angina attacks and nitroglycerin consumption.
It has a long dose-dependent hypotensive effect. The antihypertensive effect is due to the direct vasodilating effect on vascular smooth muscle. When hypertension single dose provides a clinically significant reduction in blood pressure (BP) for 24 hours (in the position of the patient “lying” and “standing”). It does not cause a sharp decline in blood pressure, reduce exercise tolerance, left ventricular ejection fraction. It reduces the degree of left ventricular hypertrophy, has anti-atherosclerotic and cardioprotective effect in ischemic heart disease (IHD). No effect on myocardial contractility and conductivity, does not cause reflex increase in heart rate (HR), inhibits platelet aggregation, increases glomerular filtration rate, has a weak natriuretic effect. In diabetic nephropathy does not increase the severity of microalbuminuria. It has no adverse effects on metabolism and plasma lipids. Time of onset of effect – 2 – 4 hours; effect duration – 24 hours.
After oral masteron hair loss slowly absorbed from the gastrointestinal tract. The mean absolute bioavailability of 64%, the maximum concentration in serum is observed after 6 – 9 hours. The concentration of stable equilibrium is reached after 7 days of treatment. Food does not affect the absorption of the drug. The mean volume of distribution of 21 l / kg body weight, indicating that most of the drug is in the tissues and relatively smaller – in the blood. Most of the drug present in the blood (95%), bind to plasma proteins.
masteron hair loss undergoes slow but extensive metabolism (90%) in the liver into inactive metabolites, has the effect of “first pass” through the liver. Metabolites not possess significant pharmacological activity.
After a single oral half-life (T 1/2 ) ranges from 31 to 48 hours when re-assigning the T 1/2 of about 45 hours. About 60% of an oral dose is excreted in the urine primarily as metabolites, 10% unchanged, and 20 – 25% in the feces and in breast milk. masteron hair loss Total clearance is 0.116 ml / sec / kg (7 ml / min / kg and 0.42 L / h / kg).
In elderly patients (65 years) masteron hair loss slowed elimination (T 1/2 – 65 hours) compared to younger patients, but the difference has no clinical significance.
Patients with liver failure elongation assumed T 1/2 and prolonged drug accumulation assignment will be higher in the body (T 1/2 to 60 hours). Renal failure has no significant effect on the kinetics of masteron hair loss. The drug crosses the blood-brain barrier. When hemodialysis is not removed.
Arterial hypertension (Monotherapy or in combination with other antihypertensive agents-governmental).
Angina, vasospastic angina (Prinzmetal angina)
– Hypersensitivity to masteron hair loss and other derivatives of dihydropyridine;
– Severe hypotension;
– Collapse, cardiogenic shock;
– Unstable angina (except Prinzmetal’s angina)
– Pregnancy and lactation;
– The age of 18 years (effectiveness and safety have been established).
Carefully: liver dysfunction, sick sinus syndrome (bradycardia, tachycardia), chronic heart failure decompensation, mild or moderate degree of hypotension, aortic stenosis, mitral stenosis, hypertrophic obstructive cardiomyopathy, acute myocardial infarction (and for 1 month after ), diabetes mellitus, older age.
Dosing and Administration
Inside, the initial dose for the treatment of hypertension and angina is 5 mg once in one day. The dose may be increased to a maximum of 10 mg once a day. When hypertension maintenance dose may be 2.5 – 5 mg per day. When angina and vasospastic angina – 5 – 10 mg per day, once. For the prevention of angina attacks – 10 mg / day.
Thin patients, patients with a short, elderly patients, patients with impaired liver function as antihypertensive, masteron hair loss is administered in an initial dose of 2.5 mg, as anti-anginal agents – 5 mg.
Do not you want to change the dose while the appointment with thiazide diuretics, beta-blockers and angiotensin-converting enzyme (ACE) inhibitors. Not required dose modification in patients with renal insufficiency.
Cardio-vascular system, palpitations, shortness of breath, marked reduction in blood pressure, fainting, vasculitis, edema (swelling of the ankles and feet), “tides” of blood to the face, rarely – arrhythmias (bradycardia, ventricular tachycardia, atrial flutter), chest pain, orthostatic hypotension, very rarely – the development or exacerbation of congestive heart failure, arrythmia, migraine.
On the part of the central nervous system: headache, dizziness, fatigue, drowsiness, mood changes, seizures, rare – loss of consciousness, hypoesthesia, nervousness, paresthesia, tremor, vertigo, fatigue, malaise, insomnia, depression, abnormal dreams, very rarely – ataxia, apathy, agitation, amnesia .
From the digestive system: nausea, vomiting, epigastric pain, rarely -increasing the level of “liver” transaminases and jaundice (caused by cholestasis), pancreatitis, dry mouth, flatulence, gingival hyperplasia, constipation or diarrhea, very rarely -gastrit, increased appetite.
With the genitourinary system: rare – pollakiuria, tenesmus, nocturia, sexual dysfunction (including reduced potency); very rarely – dysuria, polyuria.
For the skin: very rarely – dermatoxerasia, alopecia, dermatitis, purpura, skin discoloration.
Allergic reactions: pruritus, rash (including erythematous, maculopapular rash, urticaria), angioedema.
From the musculoskeletal system: rarely – arthralgia, arthrosis, myalgia (with prolonged use); very rarely – myasthenia gravis.
Other: rare – a gynecomastia, poliurikemiya, increase / decrease in body weight, thrombocytopenia, leukopenia, hyperglycemia, impaired vision, diplopia, conjunctivitis, eye pain, tinnitus, back pain, dyspnoea, epistaxis, increased sweating, thirst; very rarely – a cold clammy sweat, cough, rhinitis, parosmiya. taste disturbance, disturbance of accommodation, xerophthalmia.
Symptoms: pronounced reduction in blood pressure, tachycardia, excessive peripheral vasodilation.
Treatment: gastric lavage, the appointment of activated carbon, the maintenance function of the cardiovascular system, the control performance of the heart and lungs, limbs elevated position, control of blood volume and diuresis. To restore vascular tone – use of vasopressors (in the absence of contraindications to their use); to eliminate the effects of calcium channel blockade – intravenous calcium gluconate. Hemodialysis is not effective.
Interactions with other drugs
Inhibitors of microsomal oxidation increase the concentration of masteron hair loss in plasma, increasing the risk of side effects, and inducers of microsomal liver enzymes decrease.
Antihypertensive effect of weakening nonsteroidal anti-inflammatory drugs, especially indomethacin (sodium retention and renal prostaglandin synthesis blockade), Alpha adrenostimulyatorov, estrogens (sodium retention), sympathomimetic.
Thiazide and “loop” diuretics, beta-blockers, verapamil, ACE inhibitors and nitrates increase antianginal and antihypertensive effects.
Amiodarone, quinidine, alpha 1 adrenoblokatory, antipsychotic drugs (neuroleptics) and blockers “slow” calcium channels may increase the hypotensive effect.
It has no effect on the pharmacokinetic parameters of digoxin and warfarin.
Cimetidine does not affect the pharmacokinetics of masteron hair loss.
In a joint application with drugs lithium may increase manifestations of neurotoxicity (nausea, vomiting, diarrhea, ataxia, tremor, tinnitus).
Calcium can reduce the effect of blockers “slow” calcium channels.
Procainamide, quinidine, and other drugs that cause elongation interval QT, Reinforce the negative inotropic effect and may increase risk of significant lengthening of the interval QT.
Grapefruit juice may reduce masteron hair loss plasma concentration, but this decrease is so small that it does not significantly alter the effect of masteron hair loss.
During the period of treatment is necessary to control body weight and sodium intake, the appointment of an appropriate diet.
It is necessary to maintain dental hygiene and frequent visits to the dentist (to prevent soreness, bleeding and gingival hyperplasia).
The dosage regimen for the elderly is the same as for the patients in other age groups.
By increasing the dose should be carefully monitored for elderly patients.
Despite the lack of blockers “slow” calcium channels “cancellation” syndrome, before stopping treatment recommended a gradual reduction in dose.
masteron hair loss has no effect on plasma concentrations of K + , glucose, triglycerides, total cholesterol, LDL cholesterol, uric acid, creatinine and uric acid nitrogen.
The effect on the ability to drive the vehicle and the mechanisms
There were no reports on the effect of masteron hair loss on driving or using machinery. However, some patients in the early treatment preferably may occur drowsiness and dizziness. If this happens, the patient must take special precautions when driving and operating machinery.